MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - July 25, 2012) - MorphoSys AG /
MorphoSys to Host Q2 2012 Conference Call on August 2, 2012
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its
six months' 2012 results on August 2, 2012 at 7:00 am CEST.
At 2:00 pm CEST (1:00 pm BST, 8:00 am EDT), the Management Board of
will host a public conference call and webcast to present MorphoSys's
results for the first six months of 2012 and provide further details
Company's latest developments.
Dial-in numbers (listen only):
Germany: +49 89 2444 32975
United Kingdom: +44 20 3003 2666
USA: +1 202 204 1514
An audio replay and manuscripts of the conference will be
www.morphosys.com/conference-calls in due course.
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Company's AbD Serotec unit uses HuCAL and other technologies to generate
superior monoclonal antibodies for research and diagnostic applications.
Through its own development efforts and successful partnerships in the
pharmaceutical industry, MorphoSys has built a therapeutic pipeline of more
70 human antibody drug candidates for the treatment of cancer, rheumatoid
arthritis, and Alzheimer's disease, to name just a few. With its ongoing
commitment to new antibody technology and drug development, MorphoSys is
on engineering the medicines of tomorrow. MorphoSys is listed on the
Stock Exchange under the symbol MOR. For regular updates about MorphoSys,
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®),
RapMAT(®) and arYla(®) are registered trademarks of MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE